Tranylcypromin Chemische Eigenschaften,Einsatz,Produktion Methoden
Weltgesundheitsorganisation (WHO)
Tranylcypromine, a monoamine oxidase inhibitor (MAOI), was
introduced in 1961 for the treatment of depressive illness. By 1964 its use had been
associated with transient hypertensive crises and other adverse effects when taken
together with certain cheeses and other foods containing tyramine. This led to the
withdrawal of the drug in several countries and the suspension of marketing on a
worldwide basis by the major manufacturer pending review of these adverse
reactions. Subsequently, in response to requests from the medical profession,
tranylcypromine was resubmitted for registration with appropriate warnings in the
product information and it is now marketed in more than 30 countries.
Tranylcypromin Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
